Cardiac biomarkers play a central role in modern cardiovascular care. These blood-based tests help clinicians quickly detect heart injury, diagnose acute coronary syndrome (ACS, which includes unstable angina and heart attack), evaluate heart failure, and guide treatment decisions.
At everywhere from emergency departments evaluating chest pain to outpatient clinics managing chronic disease, cardiac biomarkers are essential tools for risk stratification, prognosis, and early diagnosis of ischemia and myocardial injury.
What Are Cardiac Biomarkers?
Cardiac biomarkers are measurable substances released into the bloodstream when the heart is under stress or injured.
“Elevated cardiac biomarker levels indicate cardiac pathology, particularly during a heart attack or heart failure,” says Xinjiang Cai, MD, PhD, a cardiologist and physician-scientist at UCLA Health.
Cardiac biomarkers such as troponin may be detectable as early as one to three hours after the onset of ischemic symptoms (e.g., chest pain) with high-sensitivity assays, although concentrations typically rise more reliably within three to six hours. Serial measurements at zero and one to three hours are usually required for accurate early diagnosis of ACS with high-sensitivity assays.
Why Are Cardiac Biomarkers Important?
“Cardiac biomarkers provide objective evidence of myocardial stress, injury, or dysfunction, and are central to diagnosis, risk stratification, management, and prognosis of cardiovascular disease,” says Dr. Cai.
In clinical practice, cardiac biomarker testing helps:
- Diagnose heart attack (myocardial infarction)
- Identify ACS
- Detect and manage heart failure
- Guide treatment decisions
- Improve long-term prognosis and monitoring
Common Types of Cardiac Biomarkers
Troponin (Troponin I and Troponin T) and High-Sensitivity Troponin (hs-cTn)
Troponin is the most important biomarker for diagnosing heart attack and myocardial injury. Troponin proteins are normally found inside heart muscle cells and help regulate contraction. When the heart muscle is damaged, even slightly, troponin leaks into the bloodstream.
High-sensitivity troponin (hs-cTn) assays are the preferred tests for detecting acute heart attack and cardiac ischemia (i.e., reduced blood flow to the heart).
“For patients with suspected heart attack, a troponin level above the 99th percentile upper reference limit indicates myocardial injury,” Dr. Cai explains.
Key points:
- Troponin I and troponin T both detect heart injury.
- A rise and/or fall in troponin levels suggests acute heart attack.
- Stable elevated troponin may indicate chronic cardiac injury or other conditions.
B-Type Natriuretic Peptide (BNP) and NT-proBNP
BNP and NT-proBNP are key biomarkers for diagnosing and managing heart failure.
BNP is a hormone released by the heart’s ventricles when they are under pressure or volume overload. It is produced as pro-BNP, which splits into BNP (active hormone) and NT-proBNP (inactive fragment).
“These levels help establish a diagnosis of heart failure, assess severity, and guide prognosis,” Dr. Cai says.
Clinically, BNP and NT-proBNP are used to:
- Diagnose heart failure
- Differentiate cardiac vs non-cardiac causes of shortness of breath
- Monitor treatment response
- Predict disease progression
Creatine Kinase-MB (CK-MB)
Creatine Kinase-MB (CK-MB) is an enzyme once widely used to detect heart attacks. However, it is less specific than troponin because it can also rise in skeletal muscle injury. Today, it is rarely used as a primary diagnostic marker.
Myoglobin
Myoglobin is an early marker of muscle injury, including heart muscle damage. It rises quickly after injury but lacks specificity for the heart, making it less useful for diagnosing ACS on its own.
Other Cardiac Biomarkers
Additional markers include lactate dehydrogenase (LDH), suppression of tumorigenicity 2 (ST2), and copeptin.
“These are rarely used in clinical cardiology because they lack specificity,” Dr. Cai notes.
When Are Cardiac Biomarkers Ordered?
Cardiac biomarker testing is commonly ordered in emergency and hospital settings when heart disease is suspected.
For patients with acute chest pain, high-sensitivity troponin testing helps rapidly rule in or rule out a heart attack using repeat measurements over one to three hours.
Dr. Cai explains:
- A rise and/or fall in cardiac troponin concentrations, with at least one value exceeding the 99th percentile upper reference limit, suggests acute myocardial injury.
- Very low hs-cTn levels below the diagnosing threshold strongly help rule out acute myocardial infarction.
For patients with shortness of breath or fluid overload, BNP and NT-proBNP help confirm or exclude heart failure and distinguish it from lung or other non-cardiac conditions.
How Are Cardiac Biomarker Tests Performed?
Cardiac biomarker testing is simple and minimally invasive. “Cardiac biomarkers are measured using a blood sample drawn from a vein in the arm and analyzed using standardized immunoassays,” Dr. Cai says.
In suspected ACS:
- Initial troponin is drawn at presentation.
- Repeat testing is done after 1–3 hours to detect changes.
In suspected heart failure:
- BNP or NT-proBNP is measured at baseline.
- Repeat testing may be used to monitor treatment response and disease progression.
Interpreting Cardiac Biomarker Results
Interpretation depends on both the absolute value and the trend over time.
Dr. Cai explains:
- Normal troponin levels that remain unchanged make heart attack unlikely.
- Rising and/or falling troponin levels above the 99th percentile suggest acute myocardial injury.
For BNP and NT-proBNP:
- Low levels make heart failure unlikely.
- Higher levels support diagnosis and severity assessment.
Serial testing improves accuracy and helps guide long-term management, especially in heart failure.
All results must be interpreted in clinical context alongside:
- Patient history and clinical symptoms
- Electrocardiogram (ECG/EKG)
- Cardiac imaging studies and other relevant diagnostic studies
Cardiac biomarker levels do not always reflect a heart attack or heart failure on their own. Several medical conditions and everyday factors can influence results, which is why interpretation must always be done in the full clinical context.
One of the most important influences is chronic kidney disease. Reduced kidney function can lead to higher baseline levels of troponin and BNP/NT-proBNP, partly due to reduced renal clearance (especially for BNP/NT-proBNP), chronic myocardial injury, and increased cardiac strain. As a result, patients with chronic kidney disease may have chronically elevated cardiac biomarkers even without an acute heart event.
Age is another important factor. Older adults tend to have slightly higher baseline levels of troponin and natriuretic peptides, compared with younger individuals, which can complicate interpretation in borderline cases. Results should be interpreted using assay-specific reference limits with consideration of age-adjusted thresholds, particularly for NT-proBNP.
Physical stress, such as strenuous exercise, can also temporarily increase troponin levels due to mild, reversible strain on heart muscle cells. In addition, serious infections like sepsis can cause elevated troponin through widespread inflammation and stress on the heart, even in the absence of a classic heart attack.
Pulmonary embolism, or a blood clot in the lungs, is another condition that can raise troponin due to sudden strain on the right side of the heart. It could be mistaken for acute coronary syndrome without careful evaluation.
On the other hand, obesity can lead to lower-than-expected BNP and NT-proBNP levels, potentially reducing the sensitivity for diagnosing heart failure.
Because of these variables, so-called “false positive troponin” or atypical BNP results can occur. So, clinicians always interpret cardiac biomarkers alongside patient history and clinical symptoms, electrocardiogram (ECG) findings, imaging and other diagnostic studies, and overall clinical assessment rather than relying on a single lab value.
Limitations and Clinical Considerations
While cardiac biomarkers are highly valuable, they are not diagnostic on their own.
Dr. Cai emphasizes that biomarker interpretation must consider the full clinical context.
For example:
- Troponin elevation does not always mean a heart attack.
- Other causes include sepsis, pulmonary embolism, stroke, and chronic kidney disease.
For BNP and NT-proBNP:
- Levels may be elevated in older adults or patients with kidney disease.
- Levels may be lower in obesity.
“Accurate diagnosis requires integration with clinical history, physical examination, ECG, and imaging,” Dr. Cai says.
Conclusion: The Role of Cardiac Biomarkers in Modern Cardiology
Cardiac biomarkers are essential tools in diagnosing and managing heart disease, including acute coronary syndrome (ACS) and heart failure. When combined with clinical evaluation, ECG, and imaging, they provide powerful insight into heart injury, ischemia, and overall cardiovascular risk.
From emergency diagnosis of heart attack to long-term monitoring of heart failure, biomarkers such as troponin, BNP, and NT-proBNP remain central to modern cardiology and personalized patient care.
